STOCK TITAN
  1. Home
  2. News
  3. ENVB

Enveric Biosciences Inc - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.

Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.

Our news collection prioritizes accuracy and timeliness, offering:

• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news

Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.

News

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Rhea-AI Summary
Enveric Biosciences (ENVB) announces the development of lead therapeutic candidate EB-373, a novel psilocin prodrug, to be published in the Journal of Medicinal Chemistry. The compound offers potential benefits for the treatment of anxiety disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
-
News

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

Rhea-AI Summary
Enveric Biosciences (ENVB) presented two posters at the Canadian Chemical Engineering Conference (CSChE 2023) showcasing the biocatalytic production of MDMA and other phenylpropylamine derivatives, as well as a synthetic biology platform for the production of novel indolethylamine derivatives as drug candidates to treat anxiety and depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
-
News

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results

Rhea-AI Summary
Enveric Biosciences, Inc. (NASDAQ: ENVB) announced significant progress in the development of neuroplastogenic small-molecule therapeutics for mental health disorders. Key highlights include the completion of several initiatives to strengthen the company's IP estate, the publication of leading scientific research, and the filing of patents for novel drug candidates and compositions of matter. The company also reported favorable results from preclinical studies and showcased the leading drug discovery and research engine behind its EVM301 Series of compounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
earnings
News

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin

Rhea-AI Summary
Enveric Biosciences has received a Notice of Allowance from the US Patent and Trademark Office for a patent application involving their lead clinical candidate, EB-373. The patent includes composition of matter claims for a family of novel prodrug derivatives of psilocin. Enveric has filed multiple composition of matter patent applications for psilocin prodrugs and has obtained seven NoAs so far. The company aims to establish a robust intellectual property position to develop improved treatments for mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none
-
News

Enveric Biosciences to Present at the Centurion One 5th Global Summit

Rhea-AI Summary
Enveric Biosciences CEO to present at Centurion One 5th Global Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
conferences
-
News

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders

Rhea-AI Summary
Enveric Biosciences initiates GLP-toxicology and safety pharmacology studies for lead prodrug candidate EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
News

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit

Rhea-AI Summary
Enveric Biosciences presents research on neuroplastogenic therapeutics at Neuropsychiatric Drug Development Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
none
-
News

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates

Rhea-AI Summary
Enveric Biosciences has reached a milestone in its Psybrary™ portfolio, surpassing 1000 synthesized compounds, which is accelerating its drug discovery process. The company anticipates nominating a lead development candidate in early 2024 for its EVM301 program, targeting major undertreated mental health indications. The novelty and diversity of the molecules in the portfolio enable robust IP-based protection strategies and potential collaborations for accelerated development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
-
News

Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry

Rhea-AI Summary
Enveric Biosciences announces the discovery of a key enzyme from cane toad and successful development of a bioproduction platform for novel indolethylamines with potential use in psychiatric medicine. The enzyme is a superior biocatalyst and has applications in the synthesis and screening of psychedelic-inspired medicines. This innovative method establishes a new approach for the production, purification, and screening of drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
News

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates

Rhea-AI Summary
Enveric Biosciences receives U.S. patent for EVM301 Series of drug candidates targeting mental health disorders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
none
Stock ENVB logo
Enveric Biosciences Inc

Nasdaq:ENVB

ENVB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ENVB Stock Data

2.89M
2.47M
0.07%
7.16%
64.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
NAPLES